[ad_1]
Futura Medical PLC's Executive Director (LON: FUM), James Barder, told Proactive London that they were about to deliver the results of their Phase III trial of a fast acting gel for dysfunction erectile by the end of the year.
The first of two studies on MED2005 started in October and involved 1,000 men in 60 centers in Europe.
A recent strategy shift at Futura has been centered on MED2005, the emergency treatment and TPR100, a topical nonsteroidal anti-inflammatory and badgesic.
Source link
